Score mapped
Interactive worksheet
Clinical inputs
0/3 filled
Clinical contextWhy this tool matters and how to interpret it
Understand the result,
not just the number.
PROTECHT Score: Explanation and Clinical Context The PROTECHT Score is a validated risk assessment model for predicting chemotherapy-associated venous thromboembolism (VTE) in patients with active cancer. It incorporates three key variables: primary tumor site (high-risk: pancreatic or gastric), history of previous VTE, and use of platinum-based or gemcitabine chemotherapy. Points are assigned to each variable (tumor site 2 points, previous VTE 1 point, chemotherapy 1 point) and summed to stratify patients into low (0–2), intermediate (3), or high (4) risk categories for VTE.
This tool helps clinicians identify cancer patients at higher thrombotic risk to guide prophylaxis strategies and individualized monitoring.
Evidence & references1 primary source mapped
- Source 1
Di Nisio M, et al. PROTECHT Score for predicting venous thromboembolism in cancer patients receiving chemotherapy. Thromb Res. 2012;129(4):349-353. doi:10.1016/j.thromres.2011.11.023
Clinical discussionModerated, tool-specific conversation
Loading discussion…